IDEAYA Biosciences' (IDYA) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• IDEAYA Biosciences (NASDAQ:IDYA) has had its "sell (D-)" rating reiterated by Weiss Ratings, reflecting ongoing concerns about its stock performance.
• The average price target for IDEAYA Biosciences is currently $43.36, with a consensus rating of "Moderate Buy" from 14 analysts, despite one analyst issuing a "Sell" rating.
• Institutional investors hold a significant 98.29% of the company's stock, highlighting strong institutional interest in IDEAYA Biosciences.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

IDYA has been the topic of a number of other research reports. Citizens Jmp started coverage on IDEAYA Biosciences in a report on Thursday, September 4th. They issued a "mkt outperform" rating and a $41.00 target price on the stock. Oppenheimer set a $36.00 target price on IDEAYA Biosciences and gave the company an "outperform" rating in a report on Monday, September 8th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Wall Street Zen raised IDEAYA Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, October 3rd. Finally, Citigroup reaffirmed a "buy" rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $43.36.

IDEAYA Biosciences Stock Down 0.3%

IDYA stock opened at $26.84 on Wednesday. IDEAYA Biosciences has a twelve month low of $13.45 and a twelve month high of $32.67. The stock's 50 day moving average is $25.16 and its 200-day moving average is $21.66. The firm has a market capitalization of $2.35 billion, a PE ratio of -7.08 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same quarter in the previous year, the company earned ($0.68) EPS. The firm's quarterly revenue was up NaN% on a year-over-year basis. On average, equities research analysts anticipate that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IDYA. Millennium Management LLC grew its stake in shares of IDEAYA Biosciences by 345.2% during the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company's stock worth $8,970,000 after acquiring an additional 424,625 shares during the period. Ensign Peak Advisors Inc grew its stake in shares of IDEAYA Biosciences by 126.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 741,833 shares of the company's stock worth $15,593,000 after acquiring an additional 414,189 shares during the period. Fiera Capital Corp grew its stake in shares of IDEAYA Biosciences by 26.6% during the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company's stock worth $32,208,000 after acquiring an additional 322,404 shares during the period. Algert Global LLC bought a new position in shares of IDEAYA Biosciences during the 1st quarter worth $5,024,000. Finally, Nuveen LLC bought a new position in shares of IDEAYA Biosciences during the 1st quarter worth $4,706,000. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.